Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

PHASE4CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

February 18, 2016

Primary Completion Date

February 23, 2021

Study Completion Date

March 25, 2021

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Nilotinib

A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.

Trial Locations (70)

12351

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

13357

Novartis Investigative Site, Berlin

13581

Novartis Investigative Site, Berlin

14195

Novartis Investigative Site, Berlin

14467

Novartis Investigative Site, Potsdam

15526

Novartis Investigative Site, Bad Saarow

18059

Novartis Investigative Site, Rostock

23563

Novartis Investigative Site, Lübeck

24105

Novartis Investigative Site, Kiel

26121

Novartis Investigative Site, Oldenburg

26389

Novartis Investigative Site, Wilhelmshaven

26655

Novartis Investigative Site, Westerstede

27356

Novartis Investigative Site, Rotenburg (Wümme)

27568

Novartis Investigative Site, Bremerhaven

30161

Novartis Investigative Site, Hanover

30170

Novartis Investigative Site, Hanover

32429

Novartis Investigative Site, Minden

33098

Novartis Investigative Site, Paderborn

34125

Novartis Investigative Site, Kassel

35392

Novartis Investigative Site, Giessen

38440

Novartis Investigative Site, Wolfsburg

38642

Novartis Investigative Site, Goslar

38820

Novartis Investigative Site, Halberstadt

39104

Novartis Investigative Site, Magdeburg

40225

Novartis Investigative Site, Düsseldorf

40479

Novartis Investigative Site, Düsseldorf

42551

Novartis Investigative Site, Velbert

44625

Novartis Investigative Site, Herne

45136

Novartis Investigative Site, Essen

45147

Novartis Investigative Site, Essen

45468

Novartis Investigative Site, Mülheim

47441

Novartis Investigative Site, Moers

48149

Novartis Investigative Site, Münster

49124

Novartis Investigative Site, Georgsmarienhütte

50671

Novartis Investigative Site, Cologne

63739

Novartis Investigative Site, Aschaffenburg

65191

Novartis Investigative Site, Wiesbaden

65812

Novartis Investigative Site, Bad Soden

66113

Novartis Investigative Site, Saarbrücken

67547

Novartis Investigative Site, Worms

68305

Novartis Investigative Site, Mannheim

69115

Novartis Investigative Site, Heidelberg

69120

Novartis Investigative Site, Heidelberg

72076

Novartis Investigative Site, Tübingen

73035

Novartis Investigative Site, Göppingen

73557

Novartis Investigative Site, Mutlangen

73614

Novartis Investigative Site, Schorndorf

74523

Novartis Investigative Site, Schwäbisch Hall

80335

Novartis Investigative Site, München

83435

Novartis Investigative Site, Bad Reichenhall

86179

Novartis Investigative Site, Augsburg

86609

Novartis Investigative Site, Donauwörth

87700

Novartis Investigative Site, Memmingen

88400

Novartis Investigative Site, Biberach

90403

Novartis Investigative Site, Nuremberg

90419

Novartis Investigative Site, Nuremberg

94036

Novartis Investigative Site, Passau

95445

Novartis Investigative Site, Bayreuth

96049

Novartis Investigative Site, Bamberg

97080

Novartis Investigative Site, Würzburg

97422

Novartis Investigative Site, Schweinfurt

97980

Novartis Investigative Site, Bad Mergentheim

99085

Novartis Investigative Site, Erfurt

09113

Novartis Investigative Site, Chemnitz

01307

Novartis Investigative Site, Dresden

06110

Novartis Investigative Site, Halle

06120

Novartis Investigative Site, Halle S

07740

Novartis Investigative Site, Jena

04103

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT02546674 - Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. | Biotech Hunter | Biotech Hunter